Our overall goal is to use the Ichor TriGrid Electroporation Device, which has been used in multiple clinical trials, for intramuscular administration of pNGVL4a-hCRTE6E7L2 DNA vaccine at escalating doses in HIV- and HIV+ patients with HPV16-associated high-grade cervical intraepithelial lesions (CIN2/3) and to examine the safety, virologic and disease outcomes in realtion to lesional expression of PD-L1/B7-H1.